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Abstract: Non-biopsy diagnosis of celiac disease is possible in children with anti-transglutaminase 2
antibodies (TGA) > 10× the upper limit of normal (ULN) and positive anti-endomysial antibodies
(EMA). Similar criteria have been suggested for adults, but evidence with different TGA assays
is scarce. We compared the performance of four TGA tests in the diagnosis of celiac disease in
cohorts with diverse pre-test probabilities. Serum samples from 836 adults with either clinical
suspicion or family risk of celiac disease were tested with four commercial TGA assays, EmA and
celiac disease-associated genetics. The diagnosis was set based on duodenal lesion or, in some cases,
using special methods. 137 (57%) patients with clinical suspicion and 85 (14%) of those with family
risk had celiac disease. Positive predictive value (PPV) for 10×ULN was 100% in each TGA test.
The first non-diagnostic investigations were encountered with ULN 1.0×–5.1× in the clinical cohort
and 1.3×–4.9× in the family cohort, respectively. Using the assays’ own cut-offs (1×ULN) the PPVs
ranged 84–100%. Serology-based diagnosis of celiac disease was accurate in adults using different
commercial kits and pre-test probabilities using 10×ULN. The results also suggest that the ULN
threshold for biopsy-omitting approach could be lower.
Keywords: celiac disease; anti-transglutaminase 2 antibodies; serology; screening; adults
1. Introduction
The estimated true prevalence of celiac disease is 1–3% [1,2], emphasizing the importance of
efficient and practical diagnostic strategy for this common condition. At the same time, diagnosis of
a life-long disease must be based on solid evidence. This has long been achieved by demonstrating
characteristic mucosal damage in duodenal biopsy, but such a histology-based approach is invasive
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and technically challenging [3,4]. Together with the high specificity of modern serological tests,
the aforesaid challenges have led to the introduction of new pediatric guidelines for diagnosing celiac
disease, enabling a non-biopsy diagnosis in selected children with anti-transglutaminase 2 antibodies
(TGA) > 10× the upper limit of normal (ULN) and positive anti-endomysial antibodies (EmA) [5].
It has been suggested that the biopsy-omitting approach could also be extended to adult patients [6,7]
and, supporting this, we recently reported a positive predictive value (PPV) of 100% for the serological
criteria in adults with variable pre-test probabilities for celiac disease [8]. The results, however, were
obtained utilizing only one TGA assay and thus cannot be directly generalized due to a lack of
standardization between the commercial tests. In fact, the artificial 10× ULN cutoff and requirement
of EmA were introduced mainly to overcome the variation in the diagnostic performance of the
TGA-based tests [5]. So far only a few-and exclusively pediatric-studies have directly compared the
accuracy of non-biopsy approach for celiac disease with different TGA assays [9].
We investigated this issue by applying four widely used commercial TGA tests in two large and
well-defined cohorts of adults with either clinical suspicion (high pre-test probability) or family risk
(moderate pre-test probability) of celiac disease.
2. Materials and Methods
2.1. Patients and Study Design
The study was conducted in the Celiac Disease Research Center, Tampere University and
Tampere University Hospital. The patients were collected from among 836 adults, who were further
categorized into two sub-cohorts based on assumed pre-test probability for celiac disease (Figure 1).
Exclusion criteria were age < 18 years and previous celiac disease diagnosis or otherwise restricted
dietary gluten consumption.
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Figure 1. Flowchart of the study. Clinical cohort (A) comprises subjects referred from primary care
due to suspicion celiac disease (CD). All cases underwent duodenal sampling. Some of the patients
with inconclusive histology received the diagnosis in a re-biopsy after one year (“Gluten challenge”).
In a subset, the diagnosis was set on the basis of special investigations and clinical, serological, and
histological response to gluten-free diet (“Special methods”). The family cohort (B) includes subjects
with ≥1 relative with celiac disease. Only seropositive subjects were referred for further investigations.
*Refusal, self-initiated gluten reduction, and exitus before biopsy.
The “clinical cohort” with expected high pre-test probability for celiac disease included 239
subjects referred from primary care due to various gastrointestinal and/or extraintestinal symptoms
suggestive of celiac disease. They might have been tested previously for celiac disease with serology.
All subjects underwent esophagogastroduodenoscopy (EGD) with systematic duodenal sampling
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(Figure 1), and also participated in research projects that included sampling and storing of sera
and whole blood that were subsequently used for testing the studied TGA assays, EmA and celiac
disease-associated genetics.
The “family cohort” with presumed moderate pre-test probability for celiac disease consisted of
597 adults, with one or more previously affected relative(s), recruited via newspaper announcements
and with the help of the Finnish Celiac Society [10].They underwent sampling and storing of blood for
serological and other celiac disease-related measurements similarly to the subjects in the clinical cohort.
The option for EGD and biopsies was offered to all subjects with suspicion of celiac disease according
to their serology results (Figure 1). The endoscopies were conducted either in Tampere University
Hospital or in other local health care units having experience in celiac disease diagnostics.
2.2. Ethics
The study protocol and patient enrollment were approved by the regional ethics committee
of Pirkanmaa Hospital District (ETL R05183, accepted 6th February 2007). All participants gave
written informed consent. The manufacturers of the TGA assays studied had no role in study design,
data analysis or interpretation or writing of the manuscript. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
2.3. Serological and Genetic Testing
Four different commercial enzyme-linked immunosorbent assays (ELISA) were utilized to test
IgA-class TGA, including Celikey (Phadia, Freiburg, Germany), Inova (QUANTA Lite h-tTG, Inova
Diagnostics, San Diego, CA, USA), Orgentec (ORG 540A, Orgentec Diagnostika, Mainz, Germany),
and Eurospital (Eu-tTG, Trieste, Italy). The cut-offs used for seropositivity were 5 U/mL, 20 U/mL,
10 U/mL and 10 U/mL respectively. The corresponding 10 × ULN were therefore 50 U/mL (Phadia),
200 U/mL (Inova), 100 U/mL (Orgentec), and 100 U/mL (Eurospital), respectively. These were also the
upper limit of measuring range for Inova and Eurospital, while those for Phadia and Orgentec were
101 U/mL and 200 U/mL, respectively. All assays studied had passed the appropriate quality controls
as requested in the non-biopsy guidelines [5].
EmA were determined in-house with indirect immunofluorescence using human umbilical cord
as an antigen [11,12]. A serum dilution 1: ≥5 was considered positive and further diluted until negative
or up to 1:4000.
The celiac disease-associated human leucocyte antigen (HLA) genotypes encoding DQ2 and
DQ8 molecules on antigen presenting cells were studied from the whole blood samples as described
elsewhere [8,10].
2.4. Histology
A minimum of four representative forceps biopsies were taken from the duodenum during each
EGD. The paraffin-embedded samples were cut, stained with hematoxylin-eosin and studied under
a light microscope. Only representative and carefully orientated mucosal sections were included
in the histopathological analysis [3]. The majority of celiac disease diagnoses were based on the
demonstration of villous atrophy and crypt hyperplasia, equivalent for Marsh 3 lesion [3,13].
In case of milder non-diagnostic lesions, participants were offered additional investigations.
Some of the subjects continued on a gluten-containing diet for one year (“gluten challenge”), after
which new biopsies were taken and the diagnosis was confirmed if Marsh 3 was present. In a subgroup
of patients with non-diagnostic lesions, special diagnostic methods were applied. These included
quantitative determination of villous height-crypt depth ratio (VH/CrD) from paraffin sections [3],
measurement of mucosal CD3+ (<37 cells/mm) and γδ+ (<4.3 cells/mm) intraepithelial lymphocytes
(IEL), and celiac disease-specific IgA deposits from frozen sections [12,14,15]. The subjects started a
one-year trial on gluten-free diet (GFD), after which the baseline investigations were repeated, and the
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diagnosis was set on the basis of positive EmA and IgA deposits and increased CD3+ and γδ+ IELs at
baseline and clinical, serological and histological response to the GFD.
Some patients with non-diagnostic duodenal histology had a bullous rash indicative of dermatitis
herpetiformis (DH), in which case the diagnosis was confirmed by demonstrating granular IgA deposits
in a skin biopsy [16].
2.5. Statistics
SPSS® Statistics version 25 (IBM, Armonk, NY, USA) was used for statistical analyses. The data are
presented either as number of cases and percentages or as medians with ranges as appropriate. PPV was
calculated by dividing the number of true positives (celiac disease) by all test positives (PPV = true
positives/[true positives +false positives]). The 95% confidence intervals (CI) for PPV are also given. As a
sensitivity analysis, PPV were calculated also considering as true positives only subjects whose celiac
disease diagnosis was based on morphological lesion (Marsh 3) in the duodenum (“worst case scenario”).
All data were analyzed blinded in collaboration with a medical statistician (H. H.).
3. Results
Altogether 125 subjects in the clinical cohort had a diagnostic duodenal lesion in either the primary
EGD or after prolonged gluten consumption, and a further 12 received the diagnosis based on special
investigations (Figure 1A, Table S1). Correspondingly, 85 subjects in the family cohort received the
diagnosis either directly or after additional investigations (Figure 1B, Table S1).
The two study cohorts had comparable median ages, while there was a female predominance in
the clinical cohort compared with the almost even gender distribution in the family cohort (Table 1).
By definition, 100% of the subjects in the family cohort had relative(s) with celiac disease, while the
corresponding proportion in the clinical cohort was approximately one-fifth. All participants receiving
the diagnosis had HLA DQ2/8 genotype consistent with celiac disease (Table 1).
Table 1. Baseline characteristics and positivity for the serological assays tested in the two study cohorts.
Clinical Cohort Family Cohort
All Subjects
n = 239 (%)
Celiac Disease
n = 137 (%)
All Subjects
n = 597 (%)
Celiac Disease
n = 85 (%)
Baseline Data
Age, median (range) 45 (17–83) 45 (18–74) 48 (18–96) 44 (18–80)
Females 72.8 79.6 53.4 50.6
Affected relative 21.1 25.8 100 100
HLA DQ2/DQ8 82.8 100 74.4 100
TGA positivity
Celikey 48.5 84.7 15.4 76.5
Orgentec 51.8 90.8 18.6 88.8
Eurospital 55.5 91.6 23.8 96.3
Inova 62.3 96.6 43.0 98.8
EmA positivity 51.5 89.8 19.3 98.8
Data was available on >85% of the subjects in each category. EmA, anti-endomysial antibodies; HLA, human
leukocyte antigen; TGA, anti-transglutaminase 2 antibodies.
The overall frequency of seropositivity using manufacturer’s cut-offs for the TGA assays tested
ranged from 48.5% to 62.3% in the clinical cohort and from 15.4% to 43.0% in the family cohort.
The corresponding numbers in those receiving a celiac disease diagnosis were 84.7–96.6% and
76.5–98.8% (Table 1).
When applying a cut-off 10× ULN, all four TGA assays showed a PPV of 100% in both clinical
(95% CIs from 88.0–100% to 92.0–100%) and family (95% CIs from 78.1–100% to 87.0–100%) cohorts
(Table 2). With the pre-defined 1× ULN cut-offs the corresponding PPVs ranged in clinical cohort
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from 83.6% to 100% (95% CIs from 76.0–89.2% to 96.0–100%) and in family cohort from 90.3% to 100%
(95% CIs from 82.0–95.2% to 90.7–99.9%), respectively (Table 2). The ULNs calculated by exploiting the
highest positive TGA value without celiac disease diagnosis for each assay ranged from 1.0× to 5.1× in
the clinical cohort and from 1.3× to 4.9× in the family cohort (Table 3).
Table 2. Positive predictive values (PPV) of the four study tests for celiac disease in the clinical and
family cohorts.
≥10× ULN a ≥1× ULN a
Positive
Subjects
(n)
Celiac
Disease
(n)
PPV
(%)
95% CI
(%)
Positive
Subjects
(n)
Celiac
Disease
(n)
PPV
(%)
95% CI
(%)
Clinical cohort
Celikey 56 56 100 92.0–100 116 116 100 96.0–100
Orgentec 36 36 100 88.0–100 113 108 95.6 89.5–98.4
Eurospital 51 51 100 91.3–100 121 109 90.1 83.0–94.5
Inova 54 54 100 91.7–100 134 112 83.6 76.0–89.2
Family cohort
Celikey 18 18 100 78.1–100 66 65 98.5 90.7–99.9
Orgentec 26 26 100 84.0–100 78 72 92.3 83.4–96.8
Eurospital 33 33 100 87.0–100 84 78 92.9 84.5–97.1
Inova 21 21 100 80.8–100 93 84 90.3 82.0–95.2
a Celikey 5.0 U/mL; Inova 20 U/mL; Orgentec 10 U/mL; Eurospital 10 U/mL. CI, confidence interval; ULN, upper
limit of normal.
Table 3. Highest positive anti-transglutaminase 2 antibody value without celiac disease diagnosis for
each study assay tested. Above these values the positive predictive value was 100% for all assays.
Clinical Cohort Family Cohort
Value, U/mL ×ULN a Value, U/mL ×ULN a
Celikey 4.8 1.0 6.6 1.3
Orgentec 32 3.2 24 2.4
Eurospital 38 3.8 38 3.8
Inova 102 5.1 98 4.9
a Celikey 5.0 U/mL; Inova 20 U/mL; Orgentec 10 U/mL; Eurospital 10 U/mL. ULN, upper limit of normal.
Assuming that only cases with Marsh 3 at any time in the duodenal biopsy or confirmed DH
were correctly diagnosed, the PPV for 10× ULN remained 100% in all tests in the family cohort but
dropped to 98.1% with QUANTA Lite and to 98.0% with Eurospital in the clinical cohort (Table S2).
The corresponding figures for 1× ULN were 76.9–94.8% in the clinical cohort and 88.2–97.0% in the
family cohort (Table S2). For Celikey and Orgentec, in which the PPV for 10x ULN remained 100% even
with “worst case scenario”, the highest values for negative biopsy were 9.6× and 5.3×ULN respectively.
EmA were positive in 89.8% and 98.8% of those with celiac disease in the clinical and family
cohorts, respectively (Table 1). Altogether, EmA was positive in 95.7% of the Celikey, 90.1% of the
Orgentec, 78.5% of the Eurospital, and 54.7% of the Inova positive patients; for those who were
eventually diagnosed with celiac disease the corresponding figures were 95.6%, 95.0%, 93.6%, and
93.4%, respectively. One subject with TGA >10× ULN in all four tests was EmA negative, as were four
subjects with only Eurospital or Inova 10× ULN. All EmA positive participants had HLA DQ2/8.
4. Discussion
All four commercial TGA assays tested here demonstrated a PPV of 100% for celiac disease when
applying the 10× ULN cutoff as specified by the European Society for Paediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN) [5]. The excellent accuracy of the serology-based criteria
observed here, if used as recommended, is in line with the majority of recent retrospective and
prospective pediatric studies [9,17–20]. Together with the previous single-assay study by us and some
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similar reports by other research groups [6,7,21–23], these findings provide further evidence that the
biopsy-sparing guidelines could also be applied to adult celiac disease patients.
Only a limited number of studies have compared the performance of two or more TGA assays in
the serological diagnosis of celiac disease in the same patients; in fact, to the best of our knowledge,
such comparisons have been reported only in children [7,9,22,24]. A few previous adult studies
have nevertheless utilized two TGA assays in separate cohorts and the result can thus be indirectly
compared with our findings [7,22]. Zanini et al. [22] found 5×ULN to be 100% specific for celiac disease
with Eurospital and Celikey. However, the ULNs used were 7 U/mL and 16 U/mL for Eurospital
(two groups) and 8 U/mL for Celikey, and thus differed from those used here. Efthymakis et al. [7]
observed PPVs of 96% and 100% for two tests with 10×ULN, but the assays used were not reported.
In children, Werkstetter et al. [9] tested the ESPGHAN criteria meticulously with eight TGA-IgA assays,
including Celikey, Inova and Eurospital, and found PPVs of 99.8–100% for >10× ULN. In addition,
Rozenberg et al. [24] reported PPVs of >99% for four automated TGA analyzers and 98% for one
ELISA kit.
Nevertheless, lower PPVs for non-biopsy approach have also been reported [25,26].
These discrepancies may, at least partially, be attributable to methodological differences, including
e.g., variable use of ULN cutoff for a given assay, lack of confirmatory EmA testing, and challenges in
applying histology as the reference standard [3,9]. A further explanation for inconclusive histology
could be early developing celiac disease presenting with only mild/patchy mucosal changes or
extraintestinal form with no apparent intestinal lesion [5,12,16], as also demonstrated here in those who
developed diagnostic lesion only after gluten challenge or who had DH. A subgroup of our patients
was also diagnosed with a so-called mild enteropathy celiac disease [12,27]. This could be criticized, but
they were rigorously investigated with sophisticated diagnostic methods and demonstrated objectively
measured treatment response, strongly supporting the presence of celiac disease. Moreover, even if they
had all been considered to be non-celiacs, the PPVs for 10× ULN would still have remained excellent.
Of note, performance of the TGA assays was not affected by the assumed pre-test probability for
celiac disease, as they worked equally well in both study cohorts. This is in line with our previous
single-assay study [8] and dispels the fears that lower pre-test probability for the disease, particularly
in screen-detected individuals, would lead to poorer diagnostic accuracy [6,28]. In fact, results of
the present and previous studies indicate that serology actually correlates better with the degree of
histological lesion than the severity or nature of the symptoms [29–32]. Likewise, in recent studies the
non-biopsy criteria have been equally reliable in symptomatic and asymptomatic children [19,25,33]
and ESPGHAN now allows a non-biopsy approach regardless of the clinical presentation [5].
There was also excellent compatibility between TGA values >10×ULN and EmA positivity. This is
important, as EmA is considered as the serological reference test that can be utilized to control for the
performance variation of the TGA assays [5]. This finding also indicate that this laborious confirmatory
step which is not feasible in all centers could be omitted in case of well-validated TGA tests with values
>10× ULN. EmA could nevertheless remain useful in borderline cases. In contrast, as also reported in
other recent studies [8,9,19], measurement of celiac disease-associated HLA did not provide additional
benefits. Accordingly, HLA is no longer required by ESPGHAN [5] although it can be valuable in the
differential diagnostics of seronegative duodenal lesion [34].
Depending on the TGA assay, lower than 10× ULN (1.0×–5.1×) also showed 100% PPV for celiac
disease, and similar findings have been reported in a few earlier studies [22,35]. This suggests that the
proportion of subjects eligible for non-biopsy approach could be increased. The lack of standardization
between the TGA tests and their different diagnostic performances nevertheless complicates this issue.
As also seen here, some of the assays are clearly intended more as sensitive screening tests whereas
others have higher specificity even with low positive values. One possible option might be serial
testing with two TGA assays, but at this point the scarcity of evidence makes it challenging to decide
optimal combination. EmA confirmation could still be useful in these circumstances, particularly if
aiming to lower the required ULN factor or when testing a new TGA combination. On the other hand,
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the chosen strategy should not be too complicated for routine clinical use. More studies designed to
investigate specifically this issue are urgently needed.
4.1. Strengths and Weaknesses
The main strengths of our study were the use of two large and well-defined cohorts of patients
with different pre-test probabilities for celiac disease [3,12]. We were also able to exploit sophisticated
diagnostic methods in inconclusive cases, although special investigations were not conducted
systemically on all participants. There were also limitations. First, EGDs were not centralized
to a single hospital, although this should not be a major source of bias as celiac disease diagnostics
are harmonized throughout Finland [36]. Second, some of the patients in the clinical cohort had
already been tested for TGA before their referral, but significant bias is again unlikely since the results
were comparable with those of the previously untested family cohort. Finally, one more potential
shortcoming was that we did not control for a possible reduction of the dietary gluten while awaiting
the biopsy.
4.2. Conclusions
We found the serology-based diagnosis of celiac disease in adults to be accurate with different
commercial TGA assays in individuals with variable pre-test probabilities, further supporting the
transition towards a less invasive diagnostic approach also after childhood. The results also suggest
that, at least in well-validated TGA assays, the specified cut-off for non-biopsy approach could be
lowered, but more research on this issue is needed.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/9/2736/s1,
Table S1: Characteristics of the 15 subjects who received a celiac disease diagnosis after special investigations and a
trial with gluten-free diet (GFD), Table S2: Positive predictive values (PPV) of the four study tests for celiac disease
in the clinical and family cohorts when counting only those cases receiving the diagnosis in routine histology
(“worst case scenario”).
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